Emmett Foundation for Urology, The Netherlands, and by research grants from the Thai government (008/2550 and 125/2550). We thank Dr. and none produced bands of the anticipated size on Western blots. More importantly, none showed a difference in staining pattern on sections or Western blots between wild-type and knockout mice. Because these antibodies were used in most studies published thus far, our findings cast doubts on the validity of the extant body of morphological knowledge of the whole family of muscarinic receptors. We formulate requirements that antibody-specification data sheets should meet and propose that journals for which IHC is a core technique facilitate consumer rating of antibodies. Certified antibodies could avoid fruitless and costly validation assays and should become the standard of commercial suppliers.(J Histochem Cytochem 56:10991111, 2008) Keywords:muscarinic receptors, antibody specificity, immunohistochemistry, Western blotting, knockout mice Theidealantiserumfor immunohistochemical (IHC) purposes should contain monospecific antibodies with a high affinity for its target epitope(s) and little nonspecific adherence to the section. The widespread availability of antibodies has made the IHC visualization of most known proteins feasible. Often, such monoclonal and polyclonal antibodies are additionally purified using protein A/G and antigen-affinity chromatography. Although these tools should yield specific, high-affinity antibodies, the quality of antisera varies. The problems of cross-reactivity of antisera that are leniolisib (CDZ 173) associated with degeneracy and mimicry in immune recognition (Cohn 2005) are well established. Furthermore, the inherent drawbacks of the use of animals to produce antisera, viz., the potential presence of antibodies against contaminants of the immunogen and/or against antigens to which the animal has been exposed earlier, are well known. For all these reasons, commercial catalogs usually extol the quality of antisera by showing their staining pattern in sections to demonstrate the signal-to-noise ratio of leniolisib (CDZ 173) the antiserum-dependent staining and on Western blots to validate that only a single protein of the expected molecular mass is recognized. Often, IHC studies with antisera, including antisera against muscarinic receptors (MRs) (Danielson et al. 2006;Mukerji et al. 2006;Sakamoto et al. 2006;Tyagi et al. 2006;Coccini et al. 2007;Danielson et al. 2007;Harrington et al. 2007), are considered to be specific on the basis of the data in specification sheets only. However, such information may pertain to special cells or tissues, whereas Western blots may show reactivity with a single protein in a specific (partially purified) extract only. In fact, the catalogs often do not even provide additional information when the size of a band in a Western blot does not correspond with the expected size of the protein (see Western Blots). Because adequate quality control data are rarely available for commercial antisera and because tissue-intrinsic controls are only applicable if previous experience with a particular antigentissue combination is available, additional validation of specificity of antibodies is still a crucial part of morphological studies. Many criteria have been used to evaluate specificity (Swaab et al. 1977;Van der Sluis and Boer 1986;van Leeuwen 1986;Saper and Sawchenko 2003;Holmseth et al. 2006;Zarghooni et al. 2007) (Table 1). Of these, a selective staining pattern, a single band of the expected size on Western blots, and the disappearance of staining after preabsorption of the antiserum with leniolisib (CDZ 173) Rabbit Polyclonal to CYC1 purified epitope are most often available for commercially available antisera, whereas the remaining, more solid criteria, such as absence of staining in tissues genetically deficient for the protein (Swaab et al. 1977;van Leeuwen 1986;Holmseth et al. 2006), identical staining patterns of antibodies raised against different epitopes on the same protein (Fischer et al. 2003), and/or correspondence between the staining pattern after ISH and IHC (Strter et al. 2001) are rarely available. The establishment of confirmatory criteria for each and every single study is financially costly, time consuming, and requires biochemical expertise. These repetitive quality controls and the confusion that is generated if they are not properly carried out can be largely avoided if the specificity data sheets of commercially available antisera meet adequate, that is, higher-quality criteria. == Table 1. == Criteria to evaluate antiserum selectivity and specificity In this study, we describe our experience with commercially available antisera against MRs. These antisera met more than one of the criteria for specificity described above, but none met all, and hence, none showed MR localization. Because these antibodies have been used in most studies published thus far, our findings cast doubt on the validity of the published body of morphological knowledge of the whole family of MRs. Based on our experience, we propose that one of the robust specificity criteria (Table 1, items d and e) and consumer rating be added to the leniolisib (CDZ 173) qualifications that are provided by commercial suppliers as validation of the reliability of antisera in their catalogs. The availability of certified antisera.